These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38539631)

  • 1. Brain-Derived Neurotrophic Factor in Multiple Sclerosis Disability: A Prospective Study.
    Vacaras V; Paraschiv AC; Iluț S; Vacaras C; Nistor C; Marin GE; Schiopu AM; Nistor DT; Vesa ȘC; Mureșanu DF
    Brain Sci; 2024 Feb; 14(3):. PubMed ID: 38539631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood levels of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (MS): A systematic review and meta-analysis.
    Karimi N; Ashourizadeh H; Akbarzadeh Pasha B; Haghshomar M; Jouzdani T; Shobeiri P; Teixeira AL; Rezaei N
    Mult Scler Relat Disord; 2022 Sep; 65():103984. PubMed ID: 35749959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort.
    de Ruiter LRJ; Loonstra FC; Jelgerhuis JR; Coerver EME; Toorop AA; van Leeuwen ICE; Noteboom S; Moraal B; Strijbis EMM; Schoonheim MM; Uitdehaag BMJ
    Mult Scler Relat Disord; 2023 Mar; 71():104568. PubMed ID: 36805177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study.
    Santinelli FB; Sebastião E; Simieli L; Antunes BM; Vieira LHP; Kalron A; Barbieri FA
    Mult Scler Relat Disord; 2022 Oct; 66():104064. PubMed ID: 35905690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Broos JY; Loonstra FC; de Ruiter LRJ; Gouda M; Fung WH; Schoonheim MM; Heijink M; Strijbis EMM; Teunissen C; Killestein J; de Vries HE; Giera M; Uitdehaag BMJ; Kooij G
    Neurology; 2023 Aug; 101(5):e533-e545. PubMed ID: 37290971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-cell BDNF expression in treatment-naïve relapsing-remitting multiple sclerosis patients and following one year of immunomodulation therapy.
    Kalinowska-Łyszczarz A; Pawlak MA; Wyciszkiewicz A; Osztynowicz K; Kozubski W; Michalak S
    Neurol Neurochir Pol; 2018 Aug; 52(4):483-489. PubMed ID: 29643001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain derived neurotrophic factor in multiple sclerosis: effect of 24 weeks endurance and resistance training.
    Wens I; Keytsman C; Deckx N; Cools N; Dalgas U; Eijnde BO
    Eur J Neurol; 2016 Jun; 23(6):1028-35. PubMed ID: 26992038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
    Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
    Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of brain-derived neurotrophic factor in patients with multiple sclerosis.
    Naegelin Y; Saeuberli K; Schaedelin S; Dingsdale H; Magon S; Baranzini S; Amann M; Parmar K; Tsagkas C; Calabrese P; Penner IK; Kappos L; Barde YA
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2251-2261. PubMed ID: 33031634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disability outcomes in early-stage African American and White people with multiple sclerosis.
    Petracca M; Palladino R; Droby A; Kurz D; Graziano N; Wang K; Riley C; Howard J; Klineova S; Lublin F; Inglese M
    Mult Scler Relat Disord; 2023 Jan; 69():104413. PubMed ID: 36399964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
    Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
    J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and cerebrospinal fluid BDNF concentrations are associated with neurological and cognitive improvement in multiple sclerosis: A pilot study.
    Yalachkov Y; Anschütz V; Maiworm M; Jakob J; Schaller-Paule MA; Schäfer JH; Reiländer A; Friedauer L; Behrens M; Steffen F; Bittner S; Foerch C
    Mult Scler Relat Disord; 2023 Mar; 71():104567. PubMed ID: 36805176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression Analysis of BDNF Gene and BDNF-AS Long Noncoding RNA in Whole Blood Samples of Multiple Sclerosis Patients: Not Always a Negative Correlation between Them.
    Gharzi V; Gangi M; Sayad A; Mazdeh M; Arsang-Jang S; Taheri M
    Iran J Allergy Asthma Immunol; 2018 Dec; 17(6):548-556. PubMed ID: 30644699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.
    Loonstra FC; de Ruiter LRJ; Koel-Simmelink MJA; Schoonheim MM; Strijbis EMM; Moraal B; Barkhof F; Uitdehaag BMJ; Teunissen C; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36543540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials.
    Shobeiri P; Karimi A; Momtazmanesh S; Teixeira AL; Teunissen CE; van Wegen EEH; Hirsch MA; Yekaninejad MS; Rezaei N
    PLoS One; 2022; 17(3):e0264557. PubMed ID: 35239684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study.
    Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E
    Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141
    [No Abstract]   [Full Text] [Related]  

  • 19. Cortical involvement determines impairment 30 years after a clinically isolated syndrome.
    Haider L; Prados F; Chung K; Goodkin O; Kanber B; Sudre C; Yiannakas M; Samson RS; Mangesius S; Thompson AJ; Gandini Wheeler-Kingshott CAM; Ciccarelli O; Chard DT; Barkhof F
    Brain; 2021 Jun; 144(5):1384-1395. PubMed ID: 33880511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the role of brain-derived neurotrophic factor in relapsing-remitting multiple sclerosis.
    Liguori M; Fera F; Gioia MC; Valentino P; Manna I; Condino F; Cerasa A; La Russa A; Clodomiro A; Paolillo A; Nisticò R; Vercillo L; Cittadella R; Quattrone A
    Genes Brain Behav; 2007 Mar; 6(2):177-83. PubMed ID: 16740142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.